SAN FRANCISCO--(BUSINESS WIRE)--Alta Partners, a leading life sciences venture capital firm, today announced a $25 million investment in Anesiva, (Nasdaq:ANSV) a late-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management. Alta Partners was the lead investor in a common stock offering valued at a total of approximately $45 million. Alta Partners has been an investor in Anesiva (formerly “Corgentech”) since November of 2000.
